Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.5 ?g per million cells in 100 ?l volume. It is recommended that the reagent be titrated for optimal performance for each application.

* PE/Dazzle? 594 has a maximum excitation of 566 nm and a maximum emission of 610 nm.

ELISA Detection^1-3 or ELISPOT Detection^4-6: The biotinylated JES6-5H4 antibody is useful as a detection antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with the purified JES6-1A12 antibody (Cat. Nos. 503701 & 503702) as capture antibody and recombinant mouse IL-2 (Cat. No. 575409) as the standard.
Flow Cytometry^8-10: The fluorochrome-labeled JES6-5H4 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IL-2 -producing cells within mixed cell populations.
Neutralization^1,7: The Ultra-LEAF? purified antibody (Endotoxin in vivo and in vitro (Cat. No. 503845-503850)) is recommended for neutralization.
Additional reported applications (for the relevant formats) include: immunoprecipitation¹, immunohistochemical staining of paraformaldehyde-fixed, saponin-treated frozen tissue sections², in vivo capture⁷, and immunocytochemistry.
Note: For testing mouse IL-2 in serum, plasma or supernatant, BioLegend's ELISA MAX? Sets (Cat. No. 431001 & 431004) are specially developed and recommended.

1. Abrams J, et al. 1992. Immunol. Rev. 127:5.
2. Sander B, et al. 1993. J. Immunol. Meth. 166:201.
3. Abrams J. 1995. Curr. Prot. Immunol. John Wiley and Sons New York. Unit 6.20.
4. Klinman D, et al. 1994. Curr. Prot. Immunol. John Wiley and Sons New York. Unit 6.19.
5. Mo X, et al. 1995. J. Virol. 69:1288.
6. Karulin A, et al. 2000. J. Immunol. 164:1862.
7. Finkelman F, et al. 2003. Curr. Prot. Immunol. John Wiley & Sons New York. Unit 6.28.
8. Ko SY, et al. 2005. J. Immunol. 175:3309. PubMed
9. Kang SS and Allen PM. 2005. J. Immunol. 174:5382.
10. Lawson BR, et al. 2007. J. Immunol. 178:5366.

1. Khakhum N, et al. 2021. NPJ Vaccines. 6:72. PubMed
2. Russell SL, et al. 2019. Cell Rep. 29:3564. PubMed
3. Levesque S, et al. 2019. Oncoimmunology. 8:e1657375. PubMed
4. Lee W, et al. 2021. J Virol. 95:e0053021. PubMed
5. Silva-Cayetano A, et al. 2020. Med. 2(3):243-262.e8. PubMed

1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press San Diego.
2. Taniguchi T, et al. 1993. Cell 73:5.
3. Nistico G. 1993. Prog. Neurobiol. 40:463.
4. Waldmann T, et al. 1993. Ann. NY Acad. Sci. 685:603.